Opiant Pharmaceuticals (OPNT) & Sabre Corporation (SABR) Critical Review
Opiant Pharmaceuticals (NASDAQ: OPNT) and Sabre Corporation (NASDAQ:SABR) are both technology companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.
Sabre Corporation pays an annual dividend of $0.56 per share and has a dividend yield of 3.2%. Opiant Pharmaceuticals does not pay a dividend. Sabre Corporation pays out 116.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
This table compares Opiant Pharmaceuticals and Sabre Corporation’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Sabre Corporation, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sabre Corporation has a consensus target price of $25.13, indicating a potential upside of 42.59%. Given Sabre Corporation’s higher probable upside, analysts clearly believe Sabre Corporation is more favorable than Opiant Pharmaceuticals.
Valuation & Earnings
This table compares Opiant Pharmaceuticals and Sabre Corporation’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$14.97 million||N/A||$5.99 million||N/A||N/A|
|Sabre Corporation||$3.48 billion||1.41||$719.33 million||$0.48||36.71|
Sabre Corporation has higher revenue and earnings than Opiant Pharmaceuticals.
Sabre Corporation beats Opiant Pharmaceuticals on 9 of the 10 factors compared between the two stocks.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Sabre Corporation Company Profile
Sabre Corporation is a technology solutions provider to the global travel and tourism industry. The Company provides software and services to a range of travel suppliers and travel buyers. The Company operates through two business segments: Travel Network, and Airline and Hospitality Solutions. Travel Network is its global business-to-business travel marketplace and consists primarily of its global distribution system (GDS) and a set of solutions that integrate with its GDS to serve travel suppliers and travel buyers. Its Airline and Hospitality Solutions business offers a portfolio of software technology products and solutions, through software-as-a-service (SaaS) and hosted delivery model, to airlines, hoteliers and other travel suppliers. The Company connects travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines and tour operators, with travel buyers in a travel marketplace.
Receive News & Ratings for Opiant Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.